A Phase 3 interventional study of Rilzabrutinib and Placebo in Immune Thrombocytopenia, sponsored by Principia Biopharma, a Sanofi Company. Completed at 155 sites in 26 countries. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Principia Biopharma, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States — 18 open to participants now, 22 under way, 9 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · United States.
Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, this one is the 2nd largest by enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2020, is one of 32 in phase 3, and was the 75th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →18 of the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
Novartis Pharmaceuticals · Sites in United States
Ages 18+
CRISPR Therapeutics AG · Sites in United States, Germany, Spain
Ages 18+
Incyte Corporation · Sites in United States, Australia, France and 4 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 43 · Phase 3 33 · Phase 4 2
First in 1999; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 232 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 42 across the 94 interventional studies, 97 across the 15 observational. Of the 80 that completed or were terminated, 46 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 110 have an industry lead sponsor. The 10 most frequent:
This study is registered under Principia Biopharma, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Principia Biopharma, a Sanofi Company is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Sanofi has 8 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
9 of the studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT04812925Phase 3argenxA Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia | 2027-10 |
| NCT07007962Phase 3SanofiStudy to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment | 2027-11-05 |
| NCT07083960Lakefront Biotherapeutics West LLCOM336 in Autoimmune Cytopenias | 2026-12 |
| NCT07786077Novartis PharmaceuticalsA Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment | 2026-12-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 110 studies in Purpura, Thrombocytopenic, Idiopathic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of \<30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in the 14 days before treatment begins. Patients received rilzabrutinib or placebo 400mg twice daily.
For each patient, the study lasted up to 60 weeks from the start of the Screening Period to the End of Study (EOS) visit. This included Screening (up to 4 weeks) through a 12 to 24-week Blinded Treatment Period followed by a 28-week Open-Label Period. Followed by a 4-week post dose follow-up.
For adult participants, the maximum duration of the long-term extension (LTE) period was 12 months from the date of the last adult participant to enter the LTE.
For pediatric participants, the maximum duration of the LTE period was 12 months from the date of the last pediatric participant to enter the LTE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
An average of 2 platelet counts at least 5 days apart of \<30,000/µL during the Screening period and no single platelet count >35,000/µL, within 14 days prior to the first dose of study drug.
- Pediatric patients must additionally be determined to need treatment for ITP as per clinical assessment by the Investigator.
Exclusion Criteria:
Treatment with rituximab or splenectomy within the 3 months prior to Study Day 1
- Patients treated with rituximab will have normal B-cell counts prior to enrollment
Had received any drug within the 30 days before receiving the first dose of study medication, or at least 5 times elimination half-life of the drug (whichever is longer); patient should not be using an investigational device at the time of dosing
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive rilzabrutinib 400mg orally twice daily for up to 24 weeks followed by 28 weeks of open label period
Drug: Rilzabrutinib
Patients receive matching placebo 400mg orally twice daily for up to 24 weeks
Drug: Placebo
400mg Caplet
Also known as: PRN1008
400mg Caplet
Also known as: PRN1008 Placebo
DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United Kingdom
Durable platelet response per guidance in regions except European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for \>=two-thirds of at least 8 non-missing weekly scheduled platelet measurements during the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy, provided that at least 2 non-missing weekly scheduled platelet measurements were at or above 50,000/mcL during the last 6 weeks of the 24-week blinded treatment period.
Time frame: Up to 24 weeks
DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United Kingdom
Durable platelet response per guidance in European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for at least 8 out of the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy.
Time frame: Up to 24 weeks
DB Period: Number of Weeks With Platelet Count >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy
Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet count \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.
Time frame: Up to 24 weeks
DB Period: Number of Weeks With Platelet Counts >=30,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy
Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet counts \>=30,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.
Time frame: Up to 24 weeks
DB Period: Time to First Platelet Count of >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and Doubled From Baseline
Time to first platelet count of \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and doubled from baseline was calculated as: (date of first occurrence of platelet response - date of first study drug intake) + 1.
Time frame: Up to 24 weeks
DB Period: Percentage of Participants Who Required Rescue Therapy
Resue therapy included intravenous immunoglobulin (Ig) or high-dose corticosteroids, platelet infusion, or anti-D Ig infusion. Percentage of participants who required rescue therapy are presented.
Time frame: Up to 24 weeks
DB Period: Change From Baseline on Item 10 (Physical Fatigue) of the Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) in Adult Participants at Week 13
ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall quality of life(QoL)(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in physical fatigue is presented.Baseline:last available value before first dose of DB study drug.
Time frame: Baseline (Day 1) and Week 13
DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale (IBLS) Assessment in Adult Participants at Week 25 Per Guidance in European Union and United Kingdom
Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by history (Hx) over previous period. In addition, 2 of these sites, skin and oral, were also assessed by physical examination (PE). These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male and postmenopausal female) at 9 sites (8 for male and postmenopausal female). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement.Baseline:last available value before first dose of DB study drug.
Time frame: Baseline (Day 1) and Week 25
DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale Assessment in Adolescent Participants at Week 25 Per Guidance in European Union and United Kingdom
Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by Hx over previous period. In addition, 2 of these sites, skin and oral, were also assessed by PE. These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male) at 9 sites (8 for male). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement. Baseline:last available value before first dose of DB study drug.
Time frame: Baseline (Day 1) and Week 25
DB-OL Period: Percentage of Participants With Stability of Response in Adult Participants
Stability of response was defined as the percentage of participants who were able to achieve stable platelet response defined as no 2 scheduled visits, at least 4 weeks apart, with a platelet count \<50,000/mcL, without an intervening visit with a platelet count \>=50,000/mcL, within a period of 24 weeks following initial achievement of the platelet response (initial platelet response defined as platelet count \>=50,000/mcL within 12 weeks of initiation of treatment with rilzabrutinib during the study). This endpoint was assessed from start of DB period through OL period.
Time frame: Up to 52 weeks
DB-OL Period: Percentage of Participants With Stability of Response in Adolescent Participants
Time frame: Up to 52 weeks
DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs) and Bleeding Treatment-Emergent Adverse Events >=Grade 2
An AE was any untoward medical occurrence in a participant or clinical investigation participant, administered a study drug and which did not necessarily had a causal relationship with the study drug. An SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period. Bleeding TEAEs Grade \>=2 (criteria mentioned in statistical analysis plan) are also presented.
Time frame: From first dose of study drug (Day 1) up to maximum DB exposure, up to 182 days (adults) and up to 175 days (adolescent)
DB Period: Plasma Concentrations of Rilzabrutinib
Blood samples were collected at specified timepoints for the analysis of plasma concentration of rilzabrutinib.
Time frame: Pre-dose at Weeks 1, 13 and 25 and 2 hours post-dose at Week 1 and 25 (adults); Pre-dose at Weeks 1, 13 and 25, 0.5, 2, 4 and 6 hours post-dose at Weeks 1 and 25 (adolescent)
DB Period: Change From Baseline in the Symptoms, Bother and Activity Domains of the Immune Thrombocytopenia-Patient Assessment Questionnaire in Adult Participants
ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall QoL(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in symptoms,bother and activity domains is presented.Baseline:last available value before first dose of DB study drug.
Time frame: Baseline (Day 1) and Week 25
DB Period: Change From Baseline in Disease-Specific Quality Of Life as Measured by the Kids' Immune Thrombocytopenia Tools (ITP-KIT) Score in Adolescent Participants
ITP-KIT was a disease-specific instrument and child self-report form designed to be completed by children \>=7 years. It comprised of total of 27 items among which 26 items were structured as Likert scales with 5 response options 1: "never", 2: "rarely", 3: "sometimes", 4: "often" and 5: "always". An additional "not applicable" option was available for items 18 to 26, which was scored as 1: the same as "never". Item 27 was a descriptive question answered "yes" or "no" which was not included in the calculation of the summary score. Instrument yielded a summary KIT score which was the summation of the items calculated as: 100 x (1- \[{sum of all valid responses - number of valid responses}/{number of valid responses\*4}\]). Scores were converted to a 0 to 100 with higher scores indicating better disease-specific QoL. Change from baseline of positive value indicated improvement. Baseline was defined as the last available value before first dose of DB study drug.
Time frame: Baseline (Day 1) and Week 25
The study was conducted at 92 centers in 25 countries for adult participants and 20 centers in 11 countries for adolescent participants. 393 adult and 51 adolescent participants were screened between 14 December 2020 to 30 September 2024, of which 191 adult and 21 adolescent participants were screen failures. Screen failures were mainly due to not meeting eligibility criteria.
| Milestone | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | OL Period: Adults: Rilzabrutinib 400 mg BID | OL Period: Adolescent: Rilzabrutinib 400 mg BID | LTE Period: Adults: Rilzabrutinib 400 mg BID | LTE Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|---|---|---|---|
| Started | 69 | 133 | 12 | 18 | 0 | 0 | 0 | 0 |
| Completed 12-week db period | 66 | 121 | 12 | 18 | 0 | 0 | 0 | 0 |
| Completed | 10 | 62 | 2 | 7 | 0 | 0 | 0 | 0 |
| Not completed | 59 | 71 | 10 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 8 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant was non-compliant to study requirements | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of response | 55 | 55 | 10 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor discretion | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | OL Period: Adults: Rilzabrutinib 400 mg BID | OL Period: Adolescent: Rilzabrutinib 400 mg BID | LTE Period: Adults: Rilzabrutinib 400 mg BID | LTE Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 180 | 30 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 115 | 10 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 65 | 20 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 21 | 4 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of response | 0 | 0 | 0 | 0 | 33 | 6 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Ongoing | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 0 |
| Milestone | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | OL Period: Adults: Rilzabrutinib 400 mg BID | OL Period: Adolescent: Rilzabrutinib 400 mg BID | LTE Period: Adults: Rilzabrutinib 400 mg BID | LTE Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 68 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of response | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor discretion | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Ongoing | 0 | 0 | 0 | 0 | 0 | 0 | 61 | 2 |
Durable platelet response per guidance in regions except European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for \>=two-thirds of at least 8 non-missing weekly scheduled platelet measurements during the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy, provided that at least 2 non-missing weekly scheduled platelet measurements were at or above 50,000/mcL during the last 6 weeks of the 24-week blinded treatment period.
| percentage of participants | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|
| DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in Regions Except European Union and United Kingdom | 0.0 (0.00 to 0.00) | 23.3 (16.12 to 30.49) | 0.0 (0.00 to 26.46) | 11.1 (1.38 to 34.71) |
Durable platelet response per guidance in European Union and United Kingdom was defined as platelet counts at or above 50,000/mcL for at least 8 out of the last 12 weeks of the 24-week blinded treatment period in the absence of rescue therapy.
| percentage of participants | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|
| DB Period: Percentage of Participants With Durable Platelet Response Per Guidance in European Union and United Kingdom | 0.0 (0.00 to 0.00) | 23.3 (16.12 to 30.49) | 0.0 (0.00 to 26.46) | 11.1 (1.38 to 34.71) |
Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet count \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.
| weeks | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|
| DB Period: Number of Weeks With Platelet Count >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy | 1.0 ± 2.14 | 7.5 ± 8.74 | 0.8 ± 1.54 | 4.2 ± 7.73 |
Number of weeks with platelet response was assessed using clinically meaningful threshold of platelet counts \>=30,000/mcL and at least doubled from baseline over the 24-week blinded treatment period in the absence of rescue therapy.
| weeks | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|
| DB Period: Number of Weeks With Platelet Counts >=30,000/mcL and at Least Doubled From Baseline in the Absence of Rescue Therapy | 1.0 ± 2.01 | 7.3 ± 8.70 | 0.6 ± 1.08 | 4.1 ± 7.76 |
Time to first platelet count of \>=50,000/mcL or between \>=30,000/mcL and \<50,000/mcL and doubled from baseline was calculated as: (date of first occurrence of platelet response - date of first study drug intake) + 1.
| days | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|
| DB Period: Time to First Platelet Count of >=50,000/mcL or Between >=30,000/mcL and <50,000/mcL and Doubled From Baseline | NA (NA to NA) | 36.0 (22.00 to 44.00) | NA (62.00 to NA) | 74.5 (9.00 to NA) |
Resue therapy included intravenous immunoglobulin (Ig) or high-dose corticosteroids, platelet infusion, or anti-D Ig infusion. Percentage of participants who required rescue therapy are presented.
| percentage of participants | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|
| DB Period: Percentage of Participants Who Required Rescue Therapy | 58.0 | 33.1 | 41.7 | 27.8 |
ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall quality of life(QoL)(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in physical fatigue is presented.Baseline:last available value before first dose of DB study drug.
| score on a scale | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID |
|---|---|---|
| DB Period: Change From Baseline on Item 10 (Physical Fatigue) of the Immune Thrombocytopenia-Patient Assessment Questionnaire (ITP-PAQ) in Adult Participants at Week 13 | -0.13 ± 2.861 | 7.95 ± 2.132 |
Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by history (Hx) over previous period. In addition, 2 of these sites, skin and oral, were also assessed by physical examination (PE). These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male and postmenopausal female) at 9 sites (8 for male and postmenopausal female). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement.Baseline:last available value before first dose of DB study drug.
| score on a scale | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID |
|---|---|---|
| DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale (IBLS) Assessment in Adult Participants at Week 25 Per Guidance in European Union and United Kingdom | 0.047 ± 0.0226 | -0.040 ± 0.0169 |
Per guidance in European Union and United Kingdom, ITP IBLS was a bleeding assessment system which comprised of 11 (10 for male) site-specific grades assessed at 9 anatomical sites by Hx over previous period. In addition, 2 of these sites, skin and oral, were also assessed by PE. These 11 grades included: skin (PE), skin (Hx), oral (PE), oral (Hx), epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage; scores ranged from 0 (none) to 2 (marked bleeding). For each participant, an IBLS score at each visit was calculated by taking average across 11 items (10 for male) at 9 sites (8 for male). Total score was calculated as mean value for all 11 grades ranging from 0 (best) to 22 (worst); higher scores indicated worse outcomes. Change of negative value indicates an improvement. Baseline:last available value before first dose of DB study drug.
| score on a scale | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|
| DB Period: Change From Baseline in Idiopathic Thrombocytopenic Purpura Bleeding Scale Assessment in Adolescent Participants at Week 25 Per Guidance in European Union and United Kingdom | -0.09 ± 0.13 | -0.04 ± 0.15 |
Stability of response was defined as the percentage of participants who were able to achieve stable platelet response defined as no 2 scheduled visits, at least 4 weeks apart, with a platelet count \<50,000/mcL, without an intervening visit with a platelet count \>=50,000/mcL, within a period of 24 weeks following initial achievement of the platelet response (initial platelet response defined as platelet count \>=50,000/mcL within 12 weeks of initiation of treatment with rilzabrutinib during the study). This endpoint was assessed from start of DB period through OL period.
| percentage of participants | DB-OL Period: Adults: Placebo in DB | DB-OL Period: Adults: Rilzabrutinib 400 mg BID in DB | DB-OL Period: Adults: Rilzabrutinib 400 mg BID |
|---|---|---|---|
| DB-OL Period: Percentage of Participants With Stability of Response in Adult Participants | 23.1 (12.83 to 33.32) | 23.3 (16.12 to 30.49) | 23.2 (17.35 to 29.11) |
Results for this outcome have not been posted.
An AE was any untoward medical occurrence in a participant or clinical investigation participant, administered a study drug and which did not necessarily had a causal relationship with the study drug. An SAE was any AE that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period. Bleeding TEAEs Grade \>=2 (criteria mentioned in statistical analysis plan) are also presented.
| Participants | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|
| Any TEAE | 52 | 111 | 10 | 15 |
| Any TESAE | 8 | 12 | 0 | 2 |
| Any Bleeding TEAEs >=Grade 2 | 8 | 5 | 0 | 2 |
Blood samples were collected at specified timepoints for the analysis of plasma concentration of rilzabrutinib.
| nanogram per milliliter (ng/mL) | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|
| Week 1: Pre-dose | 3.15 ± 24.06 | 0.00 ± 0.00 |
| Week 1: 0.5 hour post-dose | — | 34.51 ± 40.24 |
| Week 1: 2 hours post-dose | 178.95 ± 163.47 | 101.45 ± 74.07 |
| Week 1: 4 hours post-dose | — | 52.62 ± 33.70 |
| Week 1: 6 hours post-dose | — | 21.99 ± 22.49 |
| Week 13: Pre-dose | 27.05 ± 71.26 | 5.56 ± 6.88 |
| Week 25: Pre-dose | 26.31 ± 59.48 | 8.57 ± 20.47 |
| Week 25: 0.5 hour post-dose | — | 81.27 ± 70.06 |
| Week 25: 2 hours post-dose | 254.10 ± 237.11 | 163.21 ± 155.18 |
| Week 25: 4 hours post-dose | — | 72.23 ± 66.37 |
| Week 25: 6 hours post-dose | — | 21.54 ± 11.81 |
ITP-PAQ:38 items and 44 items completed by male and female respondents respectively.It included 10 scales:symptoms(6 items:1-6),fatigue/sleep(4 items:7-10),bother-physical health(3 items:11-13),activity(2 items:14-15),psychological health(5 items:16-20),fear(5 items:21-25),overall QoL(5 items:26-30),social activity(4 items:31-34),women's reproductive health(6 items:35-40),work(4 items:41-44).Responses were recorded on 4-point(1:"strongly disagree" to 4:"strongly agree"),5-point(1:"never/not at all" to 5:"all the time/extremely") or 7-point(1:"not at all" to 7:"extremely") Likert scales.Each item score:100x(\[possible maximal item score - item score\]/range).All item scores:transformed to 0 to 100 continuum and were weighted equally to derive scale scores.Total score:0(worst) to 100(best);higher scores:better QoL.Change of positive value:improvement.Change from baseline in symptoms,bother and activity domains is presented.Baseline:last available value before first dose of DB study drug.
| score on a scale | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID |
|---|---|---|
| Symptoms | 2.08 ± 12.92 | 10.28 ± 17.28 |
| Bother-physical health | -4.72 ± 19.69 | 9.98 ± 20.14 |
| Activity | -1.25 ± 25.99 | 9.96 ± 19.94 |
ITP-KIT was a disease-specific instrument and child self-report form designed to be completed by children \>=7 years. It comprised of total of 27 items among which 26 items were structured as Likert scales with 5 response options 1: "never", 2: "rarely", 3: "sometimes", 4: "often" and 5: "always". An additional "not applicable" option was available for items 18 to 26, which was scored as 1: the same as "never". Item 27 was a descriptive question answered "yes" or "no" which was not included in the calculation of the summary score. Instrument yielded a summary KIT score which was the summation of the items calculated as: 100 x (1- \[{sum of all valid responses - number of valid responses}/{number of valid responses\*4}\]). Scores were converted to a 0 to 100 with higher scores indicating better disease-specific QoL. Change from baseline of positive value indicated improvement. Baseline was defined as the last available value before first dose of DB study drug.
| score on a scale | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID |
|---|---|---|
| DB Period: Change From Baseline in Disease-Specific Quality Of Life as Measured by the Kids' Immune Thrombocytopenia Tools (ITP-KIT) Score in Adolescent Participants | 9.6 ± 6.8 | 2.0 ± 11.9 |
Collected over Adverse events and all-cause mortality (deaths) were collected: DB period: From first dose of study drug (Day 1) up to maximum DB exposure, up to 182 days for adults and up to 175 days for adolescent participants; Adult OL period: From first dose of study drug in OL period (Day 1) up to maximum OL exposure, up to 215 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Period: Adults: Placebo | 0/69 (0%) | 8/69 (11.6%) | 33/69 (47.8%) |
| DB Period: Adults: Rilzabrutinib 400 mg BID | 1/133 (0.8%) | 12/133 (9%) | 90/133 (67.7%) |
| DB Period: Adolescent: Placebo | 0/12 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| DB Period: Adolescent: Rilzabrutinib 400 mg BID | 0/18 (0%) | 2/18 (11.1%) | 15/18 (83.3%) |
| OL Period: Adults: Rilzabrutinib 400 mg BID | 0/180 (0%) | 17/180 (9.4%) | 94/180 (52.2%) |
| Event | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | OL Period: Adults: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/69 | 1/133 | 0/12 | 1/18 | 1/180 |
| Ovarian Cyst RupturedReproductive system and breast disorders | 0/69 | 0/133 | 0/12 | 1/18 | 0/180 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/69 | 1/133 | 0/12 | 0/18 | 5/180 |
| Immune ThrombocytopeniaBlood and lymphatic system disorders | 1/69 | 1/133 | 0/12 | 0/18 | 0/180 |
| Conjunctival HaemorrhageEye disorders | 1/69 | 0/133 | 0/12 | 0/18 | 0/180 |
| HaematemesisGastrointestinal disorders | 1/69 | 0/133 | 0/12 | 0/18 | 0/180 |
| Mouth HaemorrhageGastrointestinal disorders | 1/69 | 0/133 | 0/12 | 0/18 | 0/180 |
| PurpuraSkin and subcutaneous tissue disorders | 1/69 | 0/133 | 0/12 | 0/18 | 0/180 |
| Heavy Menstrual BleedingReproductive system and breast disorders | 1/69 | 0/133 | 0/12 | 0/18 | 1/180 |
| Covid-19Infections and infestations | 0/69 | 1/133 | 0/12 | 0/18 | 0/180 |
| Event | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | OL Period: Adults: Rilzabrutinib 400 mg BID |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 4/69 | 27/133 | 0/12 | 6/18 | 21/180 |
| DiarrhoeaGastrointestinal disorders | 7/69 | 43/133 | 0/12 | 1/18 | 23/180 |
| HeadacheNervous system disorders | 5/69 | 24/133 | 2/12 | 2/18 | 15/180 |
| Upper Respiratory Tract InfectionInfections and infestations | 3/69 | 5/133 | 2/12 | 2/18 | 12/180 |
| Iron Deficiency AnaemiaBlood and lymphatic system disorders | 3/69 | 1/133 | 2/12 | 1/18 | 0/180 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/69 | 6/133 | 2/12 | 2/18 | 3/180 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 1/69 | 3/133 | 2/12 | 1/18 | 2/180 |
| VomitingGastrointestinal disorders | 1/69 | 9/133 | 0/12 | 3/18 | 7/180 |
| PyrexiaGeneral disorders | 0/69 | 5/133 | 2/12 | 1/18 | 5/180 |
| Covid-19Infections and infestations | 3/69 | 17/133 | 0/12 | 1/18 | 12/180 |
Adult and adolescent randomized population included all participants from screened population who were allocated to a randomized study drug by interactive response technology regardless of whether the study drug was received or not.
| Age, Continuous(years) | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | Total |
|---|---|---|---|---|---|
| Mean | 47.1 ± 18.0 | 46.8 ± 17.1 | 14.2 ± 1.9 | 14.6 ± 1.4 | 42.7 ± 19.6 |
| Sex: Female, Male(Participants) | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | Total |
|---|---|---|---|---|---|
| Female | 49 | 78 | 7 | 9 | 143 |
| Male | 20 | 55 | 5 | 9 | 89 |
| Race/Ethnicity, Customized(Participants) | DB Period: Adults: Placebo | DB Period: Adults: Rilzabrutinib 400 mg BID | DB Period: Adolescent: Placebo | DB Period: Adolescent: Rilzabrutinib 400 mg BID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 0 | 0 | 4 |
| Asian | 24 | 40 | 8 | 8 | 80 |
| Black or African American | 0 | 1 | 0 | 1 | 2 |
| White | 40 | 85 | 3 | 6 | 134 |
| Unknown or Not Reported | 2 | 1 | 0 | 3 | 6 |
| Other | 2 | 3 | 1 | 0 | 6 |
Showing the first 100 of 155 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2020 to primary completion in Jan 2025, 49 months.
Results were first posted in Feb 2026, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 49 months is above that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 7, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilzabrutinib
Purpura, Thrombocytopenic, Idiopathic →
Principia Biopharma, a Sanofi Company →